Abstract:
A sodium caseinate-based nanoformulation of paclitaxel was developed using a scalable manufacturing process involving high-pressure homogenization and solvent removal. The resulting nanomicelles (~190 nm) demonstrated high colloidal stability, low hemolytic activity and cytotoxicity comparable to that of free paclitaxel and Abraxane®. The development of a simple and scalable sodium caseinate-based paclitaxel nanoformulation without compromising biological activity was deemed feasible.
Keywords:paclitaxel, sodium caseinate, nanomicelles, drug encapsulation, formulation development.
Received: 03.04.2026 Accepted: 10.07.2026 Published online: 29.09.2026